CDKN2A and neoplasm: As shown in Fig. 3, GE treatment led to increased expression of tumor suppressor genes, p16 and p21, whereas it decreased expression of tumor promoting genes, BMI1 and c-MYC, in both precancerous SH (Fig. 3A) and breast cancer SHR cells (Fig. 3B) at the mRNA.